{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T21:09:35Z","timestamp":1773868175589,"version":"3.50.1"},"reference-count":188,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003206","name":"Alberta Children&apos;s Hospital Foundation","doi-asserted-by":"publisher","award":["ACHF21\\u20130845"],"award-info":[{"award-number":["ACHF21\\u20130845"]}],"id":[{"id":"10.13039\/501100003206","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["420828"],"award-info":[{"award-number":["420828"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["433550"],"award-info":[{"award-number":["433550"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.smim.2025.101998","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T12:46:30Z","timestamp":1764679590000},"page":"101998","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The role of non-cancer cell infections in oncolytic virus therapy"],"prefix":"10.1016","volume":"81","author":[{"given":"Jahanara","family":"Rajwani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas J.","family":"Mahoney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.smim.2025.101998_bib1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3770","article-title":"Going viral with cancer immunotherapy","volume":"14","author":"Lichty","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.smim.2025.101998_bib2","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.smim.2025.101998_bib3","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ymthe.2018.03.007","article-title":"The Immune System in Oncolytic Immunovirotherapy: Gospel, Schism and Heresy","volume":"26","author":"Vile","year":"2018","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib4","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1158\/0008-5472.CAN-06-3974","article-title":"Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus","volume":"67","author":"Diaz","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.smim.2025.101998_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: The cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.smim.2025.101998_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/gt.2011.205","article-title":"Measles virus causes immunogenic cell death in human melanoma","volume":"20","author":"Donnelly","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2013.220","article-title":"Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies","volume":"22","author":"Workenhe","year":"2014","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib8","first-page":"450","article-title":"Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies","volume":"200","author":"van Vloten","year":"2018","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"10.1016\/j.smim.2025.101998_bib9","first-page":"1009","article-title":"Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application","volume":"31","author":"Apostolidis","year":"2007","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.smim.2025.101998_bib10","doi-asserted-by":"crossref","first-page":"28702","DOI":"10.18632\/oncotarget.25614","article-title":"D. Jedd, Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus","volume":"9","author":"Oseledchyk","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.smim.2025.101998_bib11","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1158\/1078-0432.CCR-09-0334","article-title":"Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication","volume":"15","author":"Prestwich","year":"2009","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.smim.2025.101998_bib12","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1158\/2326-6066.CIR-22-0927","article-title":"Combination IFN\u03b2 and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity","volume":"11","author":"Zheng","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.smim.2025.101998_bib13","article-title":"Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity","volume":"1","author":"Leddon","year":"2015","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.smim.2025.101998_bib14","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1038\/s41467-021-25506-6","article-title":"A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity","volume":"12","author":"Das","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2025.101998_bib15","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1002\/ijc.32325","article-title":"Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment","volume":"145","author":"Koske","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.smim.2025.101998_bib16","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/mt.2010.225","article-title":"VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling","volume":"19","author":"Wongthida","year":"2011","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib17","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ymthe.2018.01.019","article-title":"Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy","volume":"26","author":"Ricca","year":"2018","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/gt.2009.161","article-title":"Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma","volume":"17","author":"Galivo","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib19","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.omto.2020.10.011","article-title":"Decreasing the Susceptibility of Malignant Cells to Infection Does Not Impact the Overall Efficacy of Myxoma Virus-Based Oncolytic Virotherapy","volume":"19","author":"Flores","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.smim.2025.101998_bib20","doi-asserted-by":"crossref","first-page":"9933","DOI":"10.1038\/s41467-024-54111-6","article-title":"VSV(\u2206M51) drives CD8(+) T cell-mediated tumour regression through infection of both cancer and non-cancer cells","volume":"15","author":"Rajwani","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2025.101998_bib21","first-page":"3268","article-title":"Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma","volume":"6","author":"Cook","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.smim.2025.101998_bib22","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/mt.2011.26","article-title":"Targeting tumor vasculature with an oncolytic virus","volume":"19","author":"Breitbach","year":"2011","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040353","article-title":"Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus","volume":"4","author":"Kirn","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.smim.2025.101998_bib24","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1158\/1078-0432.CCR-08-2685","article-title":"Combination of viral oncolysis and tumor-specific immunity to control established tumors","volume":"15","author":"Chuang","year":"2009","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.smim.2025.101998_bib25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ccell.2015.06.009","article-title":"VEGF-Mediated Induction of PRD1-BF1\/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection","volume":"28","author":"Arulanandam","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.smim.2025.101998_bib26","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1158\/0008-5472.CAN-12-2687","article-title":"Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans","volume":"73","author":"Breitbach","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.smim.2025.101998_bib27","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1593\/neo.04265","article-title":"Multimutated Herpes Simplex Virus G207 Is a Potent Inhibitor of Angiogenesis","volume":"6","author":"Cinatl","year":"2004","journal-title":"Neoplasia"},{"key":"10.1016\/j.smim.2025.101998_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12041040","article-title":"Enhancing Antitumor Efficacy of Heavily Vascularized Tumors by RAMBO Virus through Decreased Tumor Endothelial Cell Activation","volume":"12","author":"Nair","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.smim.2025.101998_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003950","article-title":"Immunotherapy combining tumor and endothelium cell lysis with immune enforcement by recombinant MIP-3\u03b1 Newcastle disease virus in a vessel-targeting liposome enhances antitumor immunity","volume":"10","author":"Wang","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.smim.2025.101998_bib30","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1089\/hum.2005.16.765","article-title":"Oncolytic HSV Exerts Direct Antiangiogenic Activity in Ovarian Carcinoma","volume":"16","author":"Benencia","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib31","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nm.3848","article-title":"Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity","volume":"21","author":"Ilkow","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2025.101998_bib32","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s40478-020-01096-0","article-title":"Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma","volume":"8","author":"Li","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.smim.2025.101998_bib33","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/sj.mt.6300215","article-title":"Targeted Inflammation During Oncolytic Virus Therapy Severely Compromises Tumor Blood Flow","volume":"15","author":"Breitbach","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.smim.2025.101998_bib34","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1220580110","article-title":"Targeting CXCL12\/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases","volume":"110","author":"Gil","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.smim.2025.101998_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/v13040552","article-title":"Intratumoral Virotherapy with Wild-Type Newcastle Disease Virus in Carcinoma Krebs-2 Cancer Model","volume":"13","author":"Yurchenko","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.smim.2025.101998_bib36","article-title":"Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms","volume":"8","author":"Kim","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2025.101998_bib37","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1099\/0022-1317-81-11-2605","article-title":"Blood clearance rates of adenovirus type 5 in mice","volume":"81","author":"Alemany","year":"2000","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.smim.2025.101998_bib38","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2008.01.016","article-title":"Adenovirus serotype 5 hexon mediates liver gene transfer","volume":"132","author":"Waddington","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.smim.2025.101998_bib39","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/0008-5472.CAN-15-3308","article-title":"Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms","volume":"78","author":"Kim","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.smim.2025.101998_bib40","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/ijc.28395","article-title":"Tumor vascularization is critical for oncolytic vaccinia virus treatment of peritoneal carcinomatosis","volume":"134","author":"Ottolino-Perry","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.smim.2025.101998_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000857","article-title":"Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer","volume":"8","author":"Lee","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.smim.2025.101998_bib42","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/mt.2008.143","article-title":"The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma","volume":"16","author":"Liu","year":"2008","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib43","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/ijc.28747","article-title":"Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF","volume":"135","author":"Hou","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.smim.2025.101998_bib44","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature10358","article-title":"Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans","volume":"477","author":"Breitbach","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.smim.2025.101998_bib45","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/mt.2016.101","article-title":"Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers","volume":"24","author":"Downs-Canner","year":"2016","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib46","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1172\/JCI41431","article-title":"Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice","volume":"120","author":"Kottke","year":"2010","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.smim.2025.101998_bib47","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1038\/mt.2011.147","article-title":"Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy","volume":"19","author":"Kottke","year":"2011","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib48","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1172\/JCI113208","article-title":"Herpes simplex virus infection in human arterial cells. Implications in arteriosclerosis","volume":"80","author":"Hajjar","year":"1987","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.smim.2025.101998_bib49","first-page":"223","article-title":"Herpes simplex virus inhibits endothelial cell attachment and migration to extracellular matrix proteins","volume":"134","author":"Visser","year":"1989","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.smim.2025.101998_bib50","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1172\/JCI109811","article-title":"Virus infection of endothelial cells increases granulocyte adherence","volume":"65","author":"MacGregor","year":"1980","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.smim.2025.101998_bib51","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ymthe.2006.07.011","article-title":"Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy","volume":"14","author":"Liu","year":"2006","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib52","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1158\/1078-0432.CCR-06-0263","article-title":"Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors","volume":"12","author":"Liu","year":"2006","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.smim.2025.101998_bib53","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-06-3145","article-title":"Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide","volume":"67","author":"Aghi","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.smim.2025.101998_bib54","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/gt.2009.130","article-title":"Cellular effects of oncolytic viral therapy on the glioblastoma microenvironment","volume":"17","author":"Huszthy","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib55","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1038\/mt.2008.112","article-title":"Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61","volume":"16","author":"Kurozumi","year":"2008","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib56","doi-asserted-by":"crossref","first-page":"34516","DOI":"10.18632\/oncotarget.16563","article-title":"NDV-D90 suppresses growth of gastric cancer and cancer-related vascularization","volume":"8","author":"Sui","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.smim.2025.101998_bib57","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1158\/1078-0432.CCR-18-0220","article-title":"Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer","volume":"25","author":"Matuszewska","year":"2019","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.smim.2025.101998_bib58","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1158\/0008-5472.CAN-08-2628","article-title":"Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor","volume":"69","author":"Jing","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.smim.2025.101998_bib59","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/mt.2009.39","article-title":"Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivo","volume":"17","author":"Ong","year":"2009","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib60","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/mt.2010.5","article-title":"Use of adenoviral vectors to target chemotherapy to tumor vascular endothelial cells suppresses growth of breast cancer and melanoma","volume":"18","author":"Li","year":"2010","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib61","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/sj.gt.3302598","article-title":"Efficient infection of tumor endothelial cells by a capsid-modified adenovirus","volume":"13","author":"Shinozaki","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083933","article-title":"Transcriptional targeting of primary and metastatic tumor neovasculature by an adenoviral type 5 roundabout4 vector in mice","volume":"8","author":"Lu","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.smim.2025.101998_bib63","first-page":"4434","article-title":"E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer","volume":"63","author":"Fukuda","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.smim.2025.101998_bib64","doi-asserted-by":"crossref","first-page":"7278","DOI":"10.1158\/0008-5472.CAN-08-1842","article-title":"Acute Wounds Accelerate Tumorigenesis by a T Cell\u2013Dependent Mechanism","volume":"68","author":"Stuelten","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.smim.2025.101998_bib65","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1038\/s41417-022-00507-9","article-title":"Gastrointestinal cancer-associated fibroblasts expressing Junctional Adhesion Molecule-A are amenable to infection by oncolytic reovirus","volume":"29","author":"Harryvan","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121269","article-title":"Oncolytic reovirus-mediated killing of mouse cancer-associated fibroblasts","volume":"610","author":"Kurisu","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.smim.2025.101998_bib67","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1158\/1541-7786.MCR-17-0016","article-title":"Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer","volume":"15","author":"Jing","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.smim.2025.101998_bib68","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41417-020-0171-1","article-title":"In vivo antitumor activity by dual stromal and tumor-targeted oncolytic measles viruses","volume":"27","author":"Jing","year":"2020","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib69","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.immuni.2013.10.010","article-title":"The spleen in local and systemic regulation of immunity","volume":"39","author":"Bronte","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.smim.2025.101998_bib70","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/ni.2169","article-title":"Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus","volume":"13","author":"Honke","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.smim.2025.101998_bib71","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.omto.2018.06.001","article-title":"Visualizing Oncolytic Virus-Host Interactions in Live Mice Using Intravital Microscopy","volume":"10","author":"Naumenko","year":"2018","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.smim.2025.101998_bib72","first-page":"4587","article-title":"Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost Vaccination","volume":"196","author":"Bridle","year":"2016","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"10.1016\/j.smim.2025.101998_bib73","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1038\/s41467-021-22929-z","article-title":"Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination","volume":"12","author":"Roy","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2025.101998_bib74","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1084\/jem.20011666","article-title":"Virus-induced interferon alpha production by a dendritic cell subset in the absence of feedback signaling in vivo","volume":"195","author":"Barchet","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.smim.2025.101998_bib75","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1073\/pnas.0400937101","article-title":"Recognition of single-stranded RNA viruses by Toll-like receptor 7","volume":"101","author":"Lund","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.smim.2025.101998_bib76","article-title":"Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials","volume":"8","author":"Pol","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.smim.2025.101998_bib77","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/jgm.1624","article-title":"Differential biodistribution of oncolytic poxvirus administered systemically in an autochthonous model of hepatocellular carcinoma","volume":"13","author":"Baril","year":"2011","journal-title":"J. Gene Med."},{"key":"10.1016\/j.smim.2025.101998_bib78","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1593\/neo.121272","article-title":"Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity","volume":"14","author":"Li","year":"2012","journal-title":"Neoplasia N. Y. N."},{"key":"10.1016\/j.smim.2025.101998_bib79","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/ijc.29059","article-title":"Isolated limb perfusion with melphalan, tumour necrosis factor-alpha and oncolytic vaccinia virus improves tumour targeting and prolongs survival in a rat model of advanced extremity sarcoma","volume":"136","author":"Pencavel","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.smim.2025.101998_bib80","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1038\/s41598-021-81831-2","article-title":"Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs","volume":"11","author":"B\u00e9guin","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.smim.2025.101998_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2022.105166","article-title":"Preclinical safety assessment of toxicity and biodistribution of oncolytic virus HSV-1 expressing human PD-1 antibody in mice","volume":"132","author":"Wang","year":"2022","journal-title":"Regul. Toxicol. Pharmacol. RTP"},{"key":"10.1016\/j.smim.2025.101998_bib82","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/cgt.2008.83","article-title":"Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice","volume":"16","author":"Kulu","year":"2009","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib83","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00280-008-0742-6","article-title":"Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases","volume":"63","author":"Nomura","year":"2009","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.smim.2025.101998_bib84","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nature03464","article-title":"IRF-7 is the master regulator of type-I interferon-dependent immune responses","volume":"434","author":"Honda","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.smim.2025.101998_bib85","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1186\/s12885-018-4522-3","article-title":"Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells","volume":"18","author":"Jiang","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.smim.2025.101998_bib86","first-page":"1359","article-title":"In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein","volume":"29","author":"Bian","year":"2006","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.smim.2025.101998_bib87","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1007\/s10637-013-0033-x","article-title":"Bio-distribution study of Reolysin\u00ae (pelareorep) through a single intravenous infusion in Sprague-Dawley rats","volume":"31","author":"Chakrabarty","year":"2013","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.smim.2025.101998_bib88","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1126\/science.3031817","article-title":"Visualization of viral clearance in the living animal","volume":"236","author":"Verdin","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.smim.2025.101998_bib89","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1128\/jvi.62.2.545-551.1988","article-title":"Uptake of reovirus serotype 1 by the lungs from the bloodstream is mediated by the viral hemagglutinin","volume":"62","author":"Verdin","year":"1988","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2025.101998_bib90","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1089\/104303403322495070","article-title":"Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic mice","volume":"14","author":"Peng","year":"2003","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib91","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/cgt.2011.82","article-title":"Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus","volume":"19","author":"Liu","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib92","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/sj.clpt.6100409","article-title":"Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide","volume":"82","author":"Myers","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.smim.2025.101998_bib93","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1006\/mthe.2001.0329","article-title":"Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages","volume":"3","author":"Zhang","year":"2001","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib94","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11020198","article-title":"Rodents Versus Pig Model for Assessing the Performance of Serotype Chimeric Ad5\/3 Oncolytic Adenoviruses","volume":"11","author":"Koodie","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.smim.2025.101998_bib95","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1158\/0008-5472.CAN-14-3761","article-title":"Pharmacological Inhibition of \u03b23 Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity","volume":"75","author":"Browne","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.smim.2025.101998_bib96","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/gt.2014.52","article-title":"iRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy","volume":"21","author":"Puig-Saus","year":"2014","journal-title":"Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib97","article-title":"Adenovirus serotype 5 vectors with Tat-PTD modified hexon and serotype 35 fiber show greatly enhanced transduction capacity of primary cell cultures","volume":"8","author":"Yu","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.smim.2025.101998_bib98","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/jgm.1373","article-title":"Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells","volume":"11","author":"Koski","year":"2009","journal-title":"J. Gene Med."},{"key":"10.1016\/j.smim.2025.101998_bib99","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1038\/mt.2012.162","article-title":"Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery","volume":"20","author":"Coughlan","year":"2012","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib100","doi-asserted-by":"crossref","first-page":"6416","DOI":"10.1128\/JVI.00445-09","article-title":"In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery","volume":"83","author":"Coughlan","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2025.101998_bib101","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.immuni.2009.04.015","article-title":"Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in vivo","volume":"31","author":"Di Paolo","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.smim.2025.101998_bib102","doi-asserted-by":"crossref","first-page":"347","DOI":"10.18632\/oncotarget.27401","article-title":"Systemic oncolytic adenovirus delivered in mesenchymal carrier cells modulate tumor infiltrating immune cells and tumor microenvironment in mice with neuroblastoma","volume":"11","author":"Franco-Luz\u00f3n","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.smim.2025.101998_bib103","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004035","article-title":"IL-1\u03b1 and complement cooperate in triggering local neutrophilic inflammation in response to adenovirus and eliminating virus-containing cells","volume":"10","author":"Di Paolo","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.smim.2025.101998_bib104","doi-asserted-by":"crossref","first-page":"11416","DOI":"10.1073\/pnas.0403555101","article-title":"Herpes simplex virus type-1 induces IFN-alpha production via Toll-like receptor 9-dependent and -independent pathways","volume":"101","author":"Hochrein","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.smim.2025.101998_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.omto.2023.100736","article-title":"Neoadjuvant systemic oncolytic vesicular stomatitis virus is safe and may enhance long-term survivorship in dogs with naturally occurring osteosarcoma","volume":"31","author":"Makielski","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.smim.2025.101998_bib106","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1021\/acsinfecdis.8b00111","article-title":"Lymph Nodes: The Unrecognized Barrier against Pathogens","volume":"4","author":"Bogoslowski","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.smim.2025.101998_bib107","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3389\/fimmu.2019.00347","article-title":"Lymph Node Subcapsular Sinus Macrophages as the Frontline of Lymphatic Immune Defense","volume":"10","author":"Louie","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101998_bib108","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.3389\/fimmu.2018.02472","article-title":"CD169(+) Macrophages Capture and Dendritic Cells Instruct: The Interplay of the Gatekeeper and the General of the Immune System","volume":"9","author":"Grabowska","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101998_bib109","first-page":"797","article-title":"Comparative analysis of the internalization of the macrophage receptor sialoadhesin in human and mouse primary macrophages and cell lines","volume":"222","author":"De Schryver","year":"2017","journal-title":"Eur. Macrophage Dendritic Cell Soc. EMDS Spec. Issue Monocytes Dendritic Cells Macrophages Basic Res. Pathophysiol. Asp."},{"key":"10.1016\/j.smim.2025.101998_bib110","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature06287","article-title":"Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells","volume":"450","author":"Junt","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.smim.2025.101998_bib111","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/nature09118","article-title":"Subcapsular sinus macrophages prevent CNS invasion on peripheral infection with a neurotropic virus","volume":"465","author":"Iannacone","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.smim.2025.101998_bib112","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.immuni.2012.01.013","article-title":"B Cell Maintenance of Subcapsular Sinus Macrophages Protects against a Fatal Viral Infection Independent of Adaptive Immunity","volume":"36","author":"Moseman","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.smim.2025.101998_bib113","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3389\/fimmu.2019.00466","article-title":"TLR7 Controls VSV Replication in CD169(+) SCS Macrophages and Associated Viral Neuroinvasion","volume":"10","author":"Solmaz","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101998_bib114","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/hum.2010.216","article-title":"Activating Systemic T-Cell Immunity Against Self Tumor Antigens to Support Oncolytic Virotherapy with Vesicular Stomatitis Virus","volume":"22","author":"Wongthida","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib115","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001586","article-title":"Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory","volume":"9","author":"Hinterberger","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.smim.2025.101998_bib116","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.omto.2021.06.008","article-title":"Oncolytic herpes virus G47\u0394 injected into tongue cancer swiftly traffics in lymphatics and suppresses metastasis","volume":"22","author":"Uchihashi","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.smim.2025.101998_bib117","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1016\/j.vaccine.2009.03.006","article-title":"In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation","volume":"27","author":"Johnson","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.smim.2025.101998_bib118","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn2231","article-title":"Oncolytic virus\u2013mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice","volume":"14","author":"Evgin","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2025.101998_bib119","first-page":"523","article-title":"Adenovirus de-targeting from the liver","volume":"11","author":"Di Paolo","year":"2009","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.smim.2025.101998_bib120","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/sj.gt.3301515","article-title":"CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors","volume":"8","author":"Alemany","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib121","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1089\/104303403322542248","article-title":"Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates","volume":"14","author":"Smith","year":"2003","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib122","doi-asserted-by":"crossref","first-page":"11705","DOI":"10.1128\/JVI.01320-08","article-title":"Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement","volume":"82","author":"Xu","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2025.101998_bib123","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc6659","article-title":"Systemic cancer therapy with engineered adenovirus that evades innate immunity","volume":"12","author":"Atasheva","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2025.101998_bib124","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1128\/JVI.02819-06","article-title":"Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver","volume":"81","author":"Stone","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2025.101998_bib125","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1128\/JVI.79.12.7478-7491.2005","article-title":"Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity","volume":"79","author":"Shayakhmetov","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2025.101998_bib126","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1182\/blood-2006-04-008532","article-title":"Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes","volume":"108","author":"Parker","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.smim.2025.101998_bib127","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1073\/pnas.0711757105","article-title":"Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo","volume":"105","author":"Kalyuzhniy","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.smim.2025.101998_bib128","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/mt.2008.132","article-title":"Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver","volume":"16","author":"Vigant","year":"2008","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib129","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood-2009-03-208835","article-title":"Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer","volume":"114","author":"Alba","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.smim.2025.101998_bib130","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nm.3107","article-title":"Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement","volume":"19","author":"Xu","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2025.101998_bib131","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jconrel.2016.06.022","article-title":"Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: Preventing vector clearance and preserving infectivity","volume":"235","author":"Krutzke","year":"2016","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.smim.2025.101998_bib132","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/10430340152712665","article-title":"Toxicity of a first-generation adenoviral vector in rhesus macaques","volume":"13","author":"Lozier","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib133","first-page":"6070","article-title":"Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints","volume":"62","author":"Reid","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.smim.2025.101998_bib134","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/sj.gt.3301512","article-title":"Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial","volume":"8","author":"Reid","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib135","doi-asserted-by":"crossref","first-page":"8798","DOI":"10.1128\/jvi.71.11.8798-8807.1997","article-title":"The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors","volume":"71","author":"Lieber","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2025.101998_bib136","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/mt.2011.71","article-title":"Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer","volume":"19","author":"Khare","year":"2011","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib137","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.1158\/0008-5472.CAN-08-0488","article-title":"Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus","volume":"68","author":"Shashkova","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.smim.2025.101998_bib138","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/mt.2009.217","article-title":"Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus","volume":"17","author":"Shashkova","year":"2009","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib139","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1089\/10430349950018364","article-title":"Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo","volume":"10","author":"Muruve","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib140","doi-asserted-by":"crossref","DOI":"10.3390\/genes13112056","article-title":"Role of Fiber Shaft Length in Tumor Targeting with Ad5\/3 Vectors","volume":"13","author":"Richter","year":"2022","journal-title":"Genes"},{"key":"10.1016\/j.smim.2025.101998_bib141","doi-asserted-by":"crossref","DOI":"10.3390\/v13050864","article-title":"Efficient Intravenous Tumor Targeting Using the \u03b1v\u03b26 Integrin-Selective Precision Virotherapy Ad5(NULL)-A20","volume":"13","author":"Davies","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.smim.2025.101998_bib142","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1089\/hum.2020.078","article-title":"LyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor \u03b2 Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer Mouse Models","volume":"31","author":"Xu","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib143","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-18-1089","article-title":"Ad5(NULL)-A20: A Tropism-Modified, \u03b1v\u03b26 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies","volume":"24","author":"Uusi-Kerttula","year":"2018","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.smim.2025.101998_bib144","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/cgt.2014.26","article-title":"Experimental virotherapy of chemoresistant pancreatic carcinoma using infectivity-enhanced fiber-mosaic oncolytic adenovirus","volume":"21","author":"Kaliberov","year":"2014","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib145","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/mt.2014.80","article-title":"Ad5\/48 hexon oncolytic virus expressing sTGF\u03b2RIIFc produces reduced hepatic and systemic toxicities and inhibits prostate cancer bone metastases","volume":"22","author":"Xu","year":"2014","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib146","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1089\/hum.2011.003","article-title":"Systemic delivery of a novel liver-detargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model","volume":"22","author":"Zhang","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib147","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1158\/1535-7163.MCT-10-0332","article-title":"Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy","volume":"9","author":"Short","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.smim.2025.101998_bib148","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.actbio.2019.06.059","article-title":"Exploring the functions of polymers in adenovirus-mediated gene delivery: Evading immune response and redirecting tropism","volume":"97","author":"Sun","year":"2019","journal-title":"Acta Biomater."},{"key":"10.1016\/j.smim.2025.101998_bib149","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1016\/j.biomaterials.2011.11.020","article-title":"Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials","volume":"33","author":"Kim","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.smim.2025.101998_bib150","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.7150\/thno.40902","article-title":"Oligopeptide-modified poly(beta-amino ester)s-coated AdNuPARmE1A: Boosting the efficacy of intravenously administered therapeutic adenoviruses","volume":"10","author":"Brugada-Vil\u00e0","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.smim.2025.101998_bib151","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jconrel.2016.02.046","article-title":"Antitumor effect and safety profile of systemically delivered oncolytic adenovirus complexed with EGFR-targeted PAMAM-based dendrimer in orthotopic lung tumor model","volume":"231","author":"Yoon","year":"2016","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.smim.2025.101998_bib152","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jconrel.2015.10.015","article-title":"Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model","volume":"220","author":"Na","year":"2015","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.smim.2025.101998_bib153","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2013.58","article-title":"EGFR-Targeted Adenovirus Dendrimer Coating for Improved Systemic Delivery of the Theranostic NIS Gene","volume":"2","author":"Gr\u00fcnwald","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.smim.2025.101998_bib154","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jconrel.2013.03.030","article-title":"Therapeutic targeting of chitosan-PEG-folate-complexed oncolytic adenovirus for active and systemic cancer gene therapy","volume":"169","author":"Kwon","year":"2013","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.smim.2025.101998_bib155","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/humc.2016.061","article-title":"Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFN\u03b2-NIS","volume":"27","author":"Zhang","year":"2016","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.smim.2025.101998_bib156","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/mt.2008.240","article-title":"A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer","volume":"17","author":"Fong","year":"2009","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib157","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/mt.2013.181","article-title":"Antifibrotic properties of transarterial oncolytic VSV therapy for hepatocellular carcinoma in rats with thioacetamide-induced liver fibrosis","volume":"21","author":"Altomonte","year":"2013","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib158","first-page":"593","article-title":"Newcastle disease virus represses the activation of human hepatic stellate cells and reverses the development of hepatic fibrosis in mice","volume":"29","author":"Li","year":"2009","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"10.1016\/j.smim.2025.101998_bib159","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003578","article-title":"Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients","volume":"4","author":"Adair","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2025.101998_bib160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054506","article-title":"MicroRNA-mediated suppression of oncolytic adenovirus replication in human liver","volume":"8","author":"Yl\u00f6sm\u00e4ki","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.smim.2025.101998_bib161","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1038\/mt.2014.118","article-title":"Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus","volume":"22","author":"Ilett","year":"2014","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib162","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7577","article-title":"Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade","volume":"10","author":"Samson","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2025.101998_bib163","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/ijc.27918","article-title":"Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells","volume":"132","author":"Adair","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.smim.2025.101998_bib164","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1158\/1078-0432.CCR-10-3266","article-title":"Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization","volume":"17","author":"Ilett","year":"2011","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.smim.2025.101998_bib165","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/mt.2012.146","article-title":"Phase II trial of intravenous administration of Reolysin(\u00ae) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma","volume":"20","author":"Galanis","year":"2012","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib166","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1158\/2326-6066.CIR-18-0309","article-title":"Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy","volume":"6","author":"Berkeley","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.smim.2025.101998_bib167","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/cei.12562","article-title":"Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo","volume":"180","author":"El-Sherbiny","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.smim.2025.101998_bib168","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/imm.13453","article-title":"Oncolytic virus treatment differentially affects the CD56(dim) and CD56(bright) NK cell subsets in vivo and regulates a spectrum of human NK cell activity","volume":"166","author":"Wantoch","year":"2022","journal-title":"Immunology"},{"key":"10.1016\/j.smim.2025.101998_bib169","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/leu.2015.88","article-title":"Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia","volume":"29","author":"Parrish","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.smim.2025.101998_bib170","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1158\/2326-6066.CIR-21-0171","article-title":"Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients","volume":"10","author":"Samson","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.smim.2025.101998_bib171","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001803","article-title":"Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche","volume":"9","author":"M\u00fcller","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.smim.2025.101998_bib172","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1158\/1078-0432.CCR-23-0229","article-title":"Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial","volume":"29","author":"Nawrocki","year":"2023","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.smim.2025.101998_bib173","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/mt.2012.228","article-title":"Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation","volume":"21","author":"Gujar","year":"2013","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib174","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/gt.2009.29","article-title":"Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity","volume":"16","author":"Ilett","year":"2009","journal-title":"Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib175","first-page":"6018","article-title":"Reovirus activates human dendritic cells to promote innate antitumor immunity","volume":"180","author":"Errington","year":"2008","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"10.1016\/j.smim.2025.101998_bib176","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1158\/1535-7163.MCT-10-0590","article-title":"Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity","volume":"9","author":"Gujar","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.smim.2025.101998_bib177","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20221166","article-title":"OX40L-expressing recombinant modified vaccinia virus Ankara induces potent antitumor immunity via reprogramming Tregs","volume":"220","author":"Yang","year":"2023","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.smim.2025.101998_bib178","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ymthe.2023.11.003","article-title":"Oncolytic \u03b1-herpesvirus and myeloid-tropic cytomegalovirus cooperatively enhance systemic antitumor responses","volume":"32","author":"Jiang","year":"2024","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.smim.2025.101998_bib179","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1002\/(SICI)1521-4141(199910)29:10<3245::AID-IMMU3245>3.0.CO;2-X","article-title":"Inhibition of dendritic cell maturation by herpes simplex virus","volume":"29","author":"Salio","year":"1999","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.smim.2025.101998_bib180","doi-asserted-by":"crossref","first-page":"7127","DOI":"10.1128\/JVI.74.15.7127-7136.2000","article-title":"Mature dendritic cells infected with herpes simplex virus type 1 exhibit inhibited T-cell stimulatory capacity","volume":"74","author":"Kruse","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2025.101998_bib181","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00262-020-02495-x","article-title":"Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro","volume":"69","author":"Burke","year":"2020","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"10.1016\/j.smim.2025.101998_bib182","article-title":"Newcastle Disease Virus Inhibits the Proliferation of T Cells Induced by Dendritic Cells In Vitro and In Vivo","volume":"11","author":"Nan","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101998_bib183","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.virol.2018.02.011","article-title":"NDV entry into dendritic cells through macropinocytosis and suppression of T lymphocyte proliferation","volume":"518","author":"Tan","year":"2018","journal-title":"Virology"},{"key":"10.1016\/j.smim.2025.101998_bib184","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/ijc.32694","article-title":"Evaluation of Newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo","volume":"146","author":"Xu","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.smim.2025.101998_bib185","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1172\/JCI98047","article-title":"PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy","volume":"128","author":"Zamarin","year":"2018","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.smim.2025.101998_bib186","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1158\/1535-7163.MCT-20-0902","article-title":"Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity","volume":"20","author":"Harper","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.smim.2025.101998_bib187","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Zamarin","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2025.101998_bib188","doi-asserted-by":"crossref","first-page":"12160","DOI":"10.1128\/JVI.05703-11","article-title":"Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation","volume":"85","author":"Leveille","year":"2011","journal-title":"J. Virol."}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532325000703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532325000703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:07:20Z","timestamp":1773842840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532325000703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":188,"alternative-id":["S1044532325000703"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2025.101998","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of non-cancer cell infections in oncolytic virus therapy","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2025.101998","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101998"}}